Plant ID: NPO23289
Plant Latin Name: Heracleum sphondylium
Taxonomy Genus: Heracleum
Taxonomy Family: Apiaceae
NCBI TaxonomyDB:
40919
Plant-of-the-World-Online:
843179-1
Antidiarrhoeal; Antipsoriatic; Aphrodisiac; Digestive; Expectorant; Sedative
Turkey; Italy; France; Ireland; Norway; China; Belgium; Germany; Haiti; Spain; Netherlands; Denmark; Poland; Finland; Morocco; New Zealand; Russia; Bulgaria; Romania; Albania; Portugal; United Kingdom; Austria; Greece; Hungary
GPBAR1; | |
PTPN1; PTPN2; ACP1; PTPRF; CDC25B; | |
ALPL; RECQL; PLA2G1B; HSD11B1; AKR1B10; HSD17B10; POLB; | |
GAA; | |
MAPK1; | |
RORC; | |
NR1H4; | |
NFKB1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.744E-11 | 5.976E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 3.934E-10 | 2.807E-06 | AKR1B10, CYP1A2, CYP2A6, CYP2C19, CYP2D6, CYP3A4, HSD11B1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.157E-10 | 2.807E-06 | CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 9.011E-10 | 3.924E-06 | CYP1A2, CYP2A6, CYP2C19, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.244E-09 | 6.980E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 4.567E-09 | 9.945E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2D6, CYP3A4, RORC |
MF | GO:0005488; binding | GO:0020037; heme binding | 9.185E-09 | 1.667E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.081E-08 | 1.811E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.597E-08 | 2.319E-05 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.498E-08 | 4.232E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 5.879E-08 | 5.566E-05 | CYP2A13, CYP2A6, CYP2D6 |
BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 1.257E-07 | 1.013E-04 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.681E-07 | 2.290E-04 | CYP1A2, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.133E-06 | 6.168E-04 | CYP2A13, CYP2A6, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 1.480E-06 | 7.492E-04 | CYP2A13, CYP2A6 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.435E-06 | 1.876E-03 | CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 4.435E-06 | 1.876E-03 | GPBAR1, NR1H4 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 4.435E-06 | 1.876E-03 | GPBAR1, NR1H4 |
BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 8.864E-06 | 3.447E-03 | PTPN1, PTPN2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.864E-06 | 3.447E-03 | CYP1A2, CYP3A4 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 9.280E-05 | 2.768E-02 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4, HSD11B1 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.449E-10 | 3.282E-08 | HSD11B1, CYP2A6, CYP2A13, CYP2D6, CYP1A2, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.003E-10 | 3.352E-08 | HSD11B1, CYP2A6, CYP2A13, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.704E-08 | 7.609E-07 | CYP2A6, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 7.071E-07 | 1.895E-05 | HSD11B1, CYP2A6, AKR1B10, PLA2G1B, GAA, CYP1A2, ALPL, CYP2C19, CYP3A4, HSD17B10 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.712E-08 | 1.243E-06 | PLA2G1B, CYP1A2, CYP3A4, CYP2C19 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.735E-06 | 3.874E-05 | PTPN1, MAPK1, ACP1, PTPRF |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 6.316E-05 | 9.403E-04 | CYP2A6, CYP1A2, CYP3A4 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 4.486E-05 | 7.514E-04 | HSD11B1, CYP1A2, CYP3A4 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 2.932E-04 | 3.869E-03 | PTPN1, NFKB1, PTPRF |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.176E-04 | 3.869E-03 | CYP2D6, MAPK1, CYP2C19 |
09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 5.975E-04 | 6.158E-03 | PTPN1, MAPK1, PTPRF |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 5.881E-04 | 6.158E-03 | AKR1B10, GAA |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.377E-05 | 2.636E-04 | CYP2A6, CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; CDC25B; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |